Skip to main content

Two digital health startups to champion the next generation of primary care in Kenya for a better patient journey

Written by Customer Service on . Posted in Public Companies.

TAIPEI, Taiwan and NAIROBI, Kenya , March 16, 2021 (GLOBE NEWSWIRE) — iXensor Co., Ltd. (6734.TWO)
iXensor, the pioneer of mobile health, partners with Ilara Health, the health-tech company, to solve the lack of affordable medical testing for non-communicable diseases in Kenya’s primary care settings by providing integrated point-of-care diagnostics to more than a hundred of small clinics.“There is an acute need in Kenya and across the continent for early detection of metabolic diseases. With iXensor’s PixoTest, our partner facilities can do this. The PixoTest POCT System is affordable, portable, and its data integration feature allows us to use it for remote patient management, ensuring that patients can receive the highest quality of care when managing their conditions,” said Mr. Emilian Popa, the CEO of Ilara Health.More than 70% of the patients seeking medical care from small clinics require testing, and they are usually referred to larger centralized clinical centers. However, the time and cost of visiting large medical centers are enormous barriers to the majority.By connecting iXensor’s palm-size PixoTest diagnostics to Ilara Health’s Mbali Health platform, the two startups provide rapid blood testing and digital communication services to patients directly through clinics. Dr. Mwihurih Githinji commented, “Because of lifestyle changes, NCDs are becoming bigger healthcare burdens with diabetes and hypertension taking the lead. If I am able to identify diabetes or pre-diabetics earlier, then the management will be much faster.”Dr. Carson Chen, the CEO of iXensor addressed that “Being able to communicate the blood test results directly through patients’ mobile phones is a great benefit we are empowering the healthcare professionals on the front line. Together with Ilara Health, we will continue to expand the access to timely and quality medical testing for more patients in need of better care.”About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world’s first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical diagnostics across infectious diseases, women’s health, and cardiovascular diseases.
Media Contact
Spokesperson: Patrick Liao
Company Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-2-8751-1335 ext.205
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7fd3198-7a7b-4a9c-88eb-f3e27dd94060

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.